Acute Hepatic Porphyria Treatment Market Segmentation:
Distribution Channel Segment Analysis
The hospital pharmacies segment is projected to account for a lucrative share of 60% in the acute hepatic porphyria treatment market during the forecast period. In this regard, in 2023, the WHO reported that the growth of the segment is subject to its capability in distributing givosiran and hemin. The NLM study in October 2024 states that givosiran treatment has minimized the annualized rate of porphyria attacks by 97% and the annualized days of hemin by 96% in long-term follow-up. Thus, this is the evidence for a wider scope positioning of hospital pharmacy as the influencing segment in the market.
Treatment Type Segment Analysis
Prophylactic therapy is leading the treatment type segment and is dominated due to its paradigm-shifting clinical and economic value. By avoiding debilitating attacks, these treatments substantially minimize emergency department utilization and hospitalization, both significant drivers of costs. The NLM study in November 2024 states that 21.4% of patients with acute intermittent porphyria (AIP) were receiving prophylactic hemin therapy regularly every 1 to 4 weeks before starting givosiran treatment, highlighting the demand for the therapy. The Agency for Healthcare Research and Quality (AHRQ) highlights the long-term cost-effectiveness of prophylactic treatment over treatment-driven intervention. FDA-approved RNAi treatments, engineered for chronic prophylaxis, show better results in minimizing yearly attack rates and thus are the standard of care and the chief market growth driver.
Drug Class Segment Analysis
RNAi drugs will dominate the drug class segment share due to their targeted nature of action and robust clinical efficacy information. They work by eliminating the pathogenetic trigger of attacks by lowering hepatic levels of pathogenic precursors. The Orphan Drug program established by the FDA, which offers incentives to new therapies for orphan diseases, has played a pivotal role in their development and marketing. Their higher efficacy profile in the attainment of attack-free intervals, as reported in FDA-approved labeling, supports their premium pricing and solidifies their leadership as the best therapeutic class.
Our in-depth analysis of the acute hepatic porphyria treatment market includes the following segments:
|
Segments |
Subsegments |
|
Treatment Type |
|
|
Drug Class |
|
|
Route of Administration |
|
|
Distribution Channel |
|
